Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Innocutis has launched its newest product, Sitavig
INNOCUTIS has launched its newest product, Sitavig (acyclovir) 50 mg buccal tablets. Sitavig uses Lauriad technology, which consists of a tablet that sticks to the gum, above the canine tooth on the side of the lip that is infected with a cold sore, according to the company. This white- to slightlyyellow tablet is tasteless and odorless. It dissolves to provide a sustained release of medicine.
Related Videos
Related Content
